Tumor Treating Fields (TTFields) are low intensity alternating electric fields, which are tuned to interfere with the division process of cancer cells. TTFields are delivered to the body region where the tumor is located using an investigational medical device, called the NovoTTF-100L System. The system is a portable, light-weighted, battery operated device designed to deliver TTFields to the non-small cell lung cancer (NSCLC). Patients receiving TTFields need to wear four transducer arrays on their chest, which deliver the fields non-invasively to the lungs. The system is intended for continuous home use by patients.
The NovoTTF 100L System is not FDA approved to treat non-small cell lung cancer. Therefore, the safety and efficacy of TTFields in this condition is still unknown, and will be evaluated in this clinical trial.
TTFields have been approved by the FDA for treatment of adult patients suffering from recurrent and newly diagnosed glioblastoma.